REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B

Regeneron Pharmaceuticals shares outstanding 1990–2026

Regeneron Pharmaceuticals had 103,430,712 shares outstanding on 8 November 2026. Regeneron Pharmaceuticals had 106.90M diluted shares on average over the last twelve months, down 3.0% on the twelve months before. In fiscal year 2025 the average was 108.60M.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Shares outstanding

Change on the year

Fiscal yearPeriod endingShares outstandingChange on the yearBasic shares
TTM30 Sept 2026106.90M-2.99%103.00M
FY202531 Dec 2025108.60M-5.65%104.60M
FY202431 Dec 2024115.10M+1.23%107.90M
FY202331 Dec 2023113.70M+0.18%106.70M
FY202231 Dec 2022113.50M+1.16%107.10M
FY202131 Dec 2021112.20M-2.52%105.70M
FY202031 Dec 2020115.10M+0.44%107.60M
FY201931 Dec 2019114.60M-0.17%109.20M
FY201831 Dec 2018114.80M-0.96%114.80M
FY201731 Dec 2017115.91M-0.34%115.90M
FY201631 Dec 2016116.30M+0.93%116.25M
FY201531 Dec 2015115.23M+1.56%115.23M
FY201431 Dec 2014113.47M+1.95%113.41M
FY201331 Dec 2013111.29M-3.55%111.22M
FY201231 Dec 2012115.38M+27.34%111.07M
FY201131 Dec 201190.61M+9.27%90.61M
FY201031 Dec 201082.93M+3.94%82.93M
FY200931 Dec 200979.78M+1.21%79.78M
FY200831 Dec 200878.83M+18.83%78.83M
FY200731 Dec 200766.33M+14.43%66.33M
FY200631 Dec 200657.97M+3.61%57.97M
FY200531 Dec 200555.95M-0.40%55.95M
FY200431 Dec 200456.17M+11.34%55.42M
FY200331 Dec 200350.45M+14.79%50.45M
FY200231 Dec 200243.95M+4.42%43.95M
FY200131 Dec 200142.09M+19.66%42.09M
FY200031 Dec 200035.17M+11.84%35.17M
FY199931 Dec 199931.45M+1.45%31.22M
FY199831 Dec 199831.00M+6.90%30.71M
FY199731 Dec 199729.00M+18.54%29.00M
FY199631 Dec 199624.46M+23.88%24.46M
FY199531 Dec 199519.75M+4.21%19.75M
FY199431 Dec 199418.95M+14.46%18.95M
FY199331 Dec 199316.56M+7.48%16.56M
FY199231 Dec 199215.40M-0.73%15.40M
FY199131 Dec 199115.52M+1.00%15.52M
FY199031 Dec 199015.36M—15.36M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Regeneron Pharmaceuticals's shares

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.